 Home > Active Ingredient News > Drugs Articles > The adjustment of the National Medical Insurance Drug List in 2021 will start soon, and the new drugs approved before the end of June are expected to be included

The adjustment of the National Medical Insurance Drug List in 2021 will start soon, and the new drugs approved before the end of June are expected to be included

 Last Update: 2021-06-30
 Source: Internet
 Author: User

Tags

drugs therapy

antiparkinsonian drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, the National Medical Insurance Bureau publicly solicited opinions on the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan (Consultation Draft)" and "2021 National Medical Insurance Drug Catalog Adjustment Application Guidelines (Consultation Draft)", and a new round of medical insurance catalog adjustments was launched Soon
.

The “2021 National Medical Insurance Drug List Adjustment Work Plan (Draft for Solicitation of Comments)” stated that it complies with the provisions of Articles 7 and 8 of the “Interim Measures for the Administration of Basic Medical Insurance Medications” and has one of four types of non-listed western medicines and Chinese medicines.
The finished medicine shall be declared by the enterprise in accordance with the procedures, and shall be included in the scope of review of the drug catalog after being approved
.

These four situations are: from January 1, 2016 to June 30, 2021, new generic drugs approved for marketing by the National Food and Drug Administration; from January 1, 2016 to June 30, 2021, Drugs approved by the National Food and Drug Administration with major changes in indications or functional indications; drugs for the treatment of respiratory diseases related to new coronary pneumonia; drugs included in the "National Essential Drug List (2018 Edition)"

Western medicines and Chinese patent medicines in the catalogue that meet the requirements of Article 9 and Article 10 of the "Interim Measures for the Administration of Basic Medical Insurance Medications" and have one of the corresponding circumstances shall be included in the scope of drug catalogue review, or be removed from the catalogue or adjusted for payment standards
.

The scope of the drugs recalled from the catalogue is: medicines that have been revoked, revoked, or cancelled by the national drug regulatory authority; medicines that are assessed to be more risky than benefits, should be considered for entry into the catalog before January 1, 2016, and January 2016 Drugs for which there is no purchase record on the national drug procurement platform from January 1 to June 30, 2021

In addition, according to the draft for comments, at the application stage, the National Medical Insurance Administration Medical Insurance Center will publicize the drugs that have passed the formal review and the drug approval, price and other materials submitted by the company

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.